- Theralase Technologies has donated some of its technology to help advance university studies into Parkinson’s Disease treatment
- The Toronto-based pharmaceutical company stated it had donated two Theralase TLC-2400 Cool Laser Therapy systems to the University of Windsor to help in the research and development of a novel treatment for patients suffering from Parkinson’s Disease
- Theralase’s CLT is one of the few technologies in the world able to penetrate the human skull, promoting anti-inflammatory responses and stimulating neurons to promote healing
- Shares of Theralase last traded at $0.20 per share
Theralase Technologies (TSXV:TLT) has donated some of its technology to help advance university studies into Parkinson’s Disease treatment.
In a news release, the Toronto-based pharmaceutical company stated it had donated two Theralase TLC-2400 Cool Laser Therapy (CLT) systems to the University of Windsor to help in the research and development of a novel treatment for patients suffering from Parkinson’s Disease.
Theralase revealed it is working in collaboration with researchers at the University of Windsor’s Faculty of Human Kinetics and a Windsor-based chiropractor to conduct this clinical study.
The study is focused on how Theralase CLT can be used to treat Parkinson’s. Theralase’s CLT, with its super-pulsed laser technology, is one of the few technologies in the world able to non-invasively penetrate the human skull, promoting anti-inflammatory responses and stimulating neurons to promote healing from the disease.
With no known cure, Parkinson’s is a neurological disorder where the brain loses its ability to control movement. People with Parkinson’s may struggle with walking, talking, memory loss, chronic pain, fatigue, depression, anxiety, loss of the sense of smell and other non-motor impairments.
Around 1 million people in North America and 10 million people worldwide suffer from Parkinson’s. From 2019-2020, the Canadian Chronic Disease Surveillance System (CCDSS) reported more than 12,500 new diagnoses of Parkinson’s and, overall more than 103,000 cases of Parkinson’s were reported in Canada. Nearly 90,000 people are diagnosed annually in the United States, according to Parkinson’s Foundation data.
According to a study by the Lewin Group, supported by the Michael J. Fox Foundation and the Parkinson’s Foundation, about US$25.4 billion was spent in the United States annually on direct medical costs of Parkinson’s and another US$26.5 billion was lost in missed work, lost wages, early forced retirement and family caregiver time.
“The primary objective of a double blind randomized controlled clinical study is to remove bias from patients and practitioners by masking whether the patient is treated with a true Theralase TLC-2000 CLT system or placebo,” Dr. Anthony Bain, designer of the clinical study and University of Windsor professor stated. “This clinical data will allow us to scientifically and clinically determine the impact that Theralase CLT is making on this deadly disease.”
“After decades of research into Theralase CLT technology, the technology is very well suited to implement a multitargeted therapeutic approach; specifically: normalizing microglia activity, reducing neuroinflammation, modulating immune responses and promoting neuroprotection,” Dr. Arkady Mandel, Chief Scientific Officer at Theralase added. “This helps transform Parkinson’s vicious cycle of neurodegeneration/neuroinflammation and as a result significantly improves the quality of life of patients with Parkinson’s. I look forward to successfully completing the clinical study to allow widespread adoption of this highly effective technology worldwide.”
Theralase is a clinical-stage pharmaceutical company focused on the research and development of light-activated compounds, their associated drug formulations and the light systems that activate them.
Shares of Theralase last traded at $0.20 per share.
Join the discussion: Find out what everybody’s saying about this stock on the Theralase Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
